Valneva SE has appointed Dipal Patel as chief commercial officer and management board member to help it prepare for the potential market launch in 2023 of its vaccine against chikungunya virus. Chikungunya is a mosquito-borne virus that can lead to fever and joint pain. There is currently no vaccine to prevent, or medicine to treat, the virus. Ms Patel was previously global commercial head for the shingles vaccine, Shingrix, at GSK Plc.
She holds bachelor of science and master of business administration degrees from Macquarie University in Australia.
Valneva announced the appointment on 17 November 2022.
Copyright 2022 Evernow Publishing Ltd